All AbMole products are for research use only, cannot be used for human consumption.
Fludarabine (NSC 118218) is a purine analog that inhibits DNA synthesis. Fludarabine is used in the treatment of hematological malignancies (cancers of blood cells such as leukemias and lymphomas). Fludarabine inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase. Fludarabine markedly inhibited VSMC proliferation in cell culture. Furthermore, fludarabine reduced neointimal formation after balloon angioplasty in a dose-dependent manner, and fludarabine-eluting stents reduced neointimal hyperplasia by approximately 50%. Fludarabine induces apoptosis of cancer cells and RNA transcription inhibitor. Fludarabine also induces significant reduction of STAT-1 phosphorylation, whereas it does not change JAK2 activation. Fludarabine exhibits antiproliferative activity (IC50 = 1.54 μM in RPMI cells) and triggers apoptosis through increasing Bax and decreasing Bid, XIAP and survivin expression. Fludarabine displays anticancer activity against hematological malignancies in vivo.
Int Immunopharmacol. 2024 Feb 15;128:111563.
Regulation of IL-10 expression and function by JAK-STAT in CD8+ T cells
Fludarabine purchased from AbMole
Oncol Res . 2024 Jul 17;32(8):1359-1368.
Analysis of the role of dihydromyricetin derived from vine tea (Ampelopsis grossedentata) on multiple myeloma by activating STAT1/RIG-I axis
Fludarabine purchased from AbMole
Front Immunol. 2022 Feb 7;13:820685.
The Study on the Regulation of Th Cells by Mesenchymal Stem Cells Through the JAK-STAT Signaling Pathway to Protect Naturally Aged Sepsis Model Rats
Fludarabine purchased from AbMole
| Molecular Weight | 285.23 |
| Formula | C10H12FN5O4 |
| CAS Number | 21679-14-1 |
| Solubility (25°C) | DMSO 27 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related STAT Products |
|---|
| HP590
HP590 is an orally active, novel and potent STAT3 inhibitor (STAT3 luciferase activity: IC50=27.8 nM; ATP inhibition: IC50=24.7 nM). |
| 1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea
STAT3-IN-7 is a Sorafenib analogue and potently inhibits the phosphorylation of STAT3. |
| HJC0123
HJC0123 is a novel STAT3 inhibitor that suppresses the fibrogenic properties of HSCs. HJC0123 reduced the phosphorylation, nuclear translocation, and transcriptional activity of STAT3. HJC0123 treatment resulted in the inhibition of HSCs proliferation at submicromolar concentrations. It decreased the expression of STAT3-regulated proteins, induced cell cycle arrest, promoted apoptosis and downregulated SOCS3. |
| ODZ10117
ODZ10117 is a small molecule inhibitor of STAT3. ODZ10117 inhibited migration and invasion and induced apoptotic cell death by targeting STAT3 in glioblastoma cells. |
| OPB-111077
OPB-111077 is a first-in-class, novel, oral inhibitor of STAT3 and mitochondrial oxidative phosphorylation (OXPHOS) with anticancer activity. OPB-111077 inhibits mitochondrial respiratory chain complex I, which leads to inhibition of energy production and activation of the AMPK-mTOR energy stress sensor pathway. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
